

# Prof. MEHMET MURAT KULOĞLU

## Personal Information

**Office Phone:** [+90 242 249 6841](tel:+902422496841) Extension: 6841

**Email:** [kuloglum@akdeniz.edu.tr](mailto:kuloglum@akdeniz.edu.tr)

**Web:** <https://avesis.akdeniz.edu.tr/kuloglum>

**Address:** Akdeniz Üniversitesi Tıp Fakültesi Ruh Sağlığı ve Hastalıkları AD. Dumlupınar Bulvarı Kampüs 07059 Konyaaltı-ANTALYA

## Education Information

Expertise In Medicine, Ataturk University, Tıp Fakültesi, Ruh Sağlığı Ve Hastalıkları, Turkey 1991 - 1995

Postgraduate, Firat University, School Of Medicine, Ruh Sağlığı Ve Hastalıkları, Turkey 1983 - 1989

## Foreign Languages

English, B2 Upper Intermediate

## Dissertations

Expertise In Medicine, Şizofrenik Hastalardaki Negatif Belirtilerin Tedavisinde Dopamin Agonisti Bromokriptinin Etkinliği, Ataturk University, Tıp Fakültesi, Ruh Sağlığı Ve Hastalıkları, 1995

## Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Psychiatry

## Academic Titles / Tasks

Professor, Akdeniz University, Faculty of Medicine, Dahili Tıp Bilimleri, 2013 - Continues

Professor, Firat University, School Of Medicine, Dahili Tıp Bilimleri, 2009 - 2013

Associate Professor, Firat University, School Of Medicine, Dahili Tıp Bilimleri, 2008 - 2009

Associate Professor, Firat University, School Of Medicine, Dahili Tıp Bilimleri, 2003 - 2004

Assistant Professor, Firat University, School Of Medicine, Dahili Tıp Bilimleri, 1997 - 2003

## Academic and Administrative Experience

Akdeniz University, Tıp Fakültesi Dahili Tıp Bilimleri, 2014 - Continues

Akdeniz University, Alanya Tıp Fakültesi, 2014 - 2015

Akdeniz University, Tıp Fakültesi Klinik Araştırmalar Etik Kurulu, 2013 - 2014

Firat University, Hastanesi, 2003 - 2003

Firat University, Tıbbi Etik Kurul, 2001 - 2002

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.**  
ERDOĞAN A., TOPCUOĞLU M., COŞKUN M. N., CİNEMRE B., KULAKSIZOĞLU B., KULOĞLU M. M.  
Human psychopharmacology, vol.37, no.2, 2022 (SCI-Expanded)
- II. **Sociodemographic and clinical characteristics of patients admitted to an addiction center**  
ERDOĞAN A., Dilcen H. Y., CİNEMRE B., KULAKSIZOĞLU B., İNAN D., Kuloglu M. M.  
JOURNAL OF SUBSTANCE USE, vol.27, no.3, pp.321-327, 2022 (SSCI)
- III. **Follow-up of serum naltrexone levels after naltrexone implant in opioid use disorder**  
KULAKSIZOĞLU B., ERDOĞAN A., CİNEMRE B., TOPCUOĞLU M., COŞKUN M. N., Ozdemir M., Bingol M. S., Kuloglu M. M.  
Heroin Addiction and Related Clinical Problems, vol.23, no.3, pp.23-28, 2021 (SSCI)
- IV. **Distribution of Hepatitis C Virus (HCV) Genotypes Among Intravenous Drug and Non-Drug User Patients**  
Erman Daloglu A., PARKAN Ö. M., ERDOĞAN A., Peker B. O., Can Sarinoglu R., SAĞLIK İ., İNAN D., Kuloglu M. M., MUTLU D., ÖNGÜT G., et al.  
MIKROBIYOLOJİ BULTENİ, vol.55, no.1, pp.30-40, 2021 (SCI-Expanded)
- V. **Comparison of oral naltrexone and naltrexone implant treatment in alcohol use disorders Alkol kullanım bozukluğunda oral naltrekson ve naltrekson implant tedavisinin karşılaştırılması**  
CİNEMRE B., ERDOĞAN A., KULAKSIZOĞLU B., METİN Ö., Kuloglu M. M.  
Anadolu Psikiyatri Dergisi, vol.21, no.5, pp.477-482, 2020 (SCI-Expanded)
- VI. **Turkish adaptation of Kessler Psychological Distress Scale: validity and reliability study**  
Altun Y., Ozen M., Kuloglu M. M.  
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.20, pp.23-31, 2019 (SCI-Expanded)
- VII. **Evaluation of Subclinical Left Ventricular Systolic Dysfunction in Chronic Asymptomatic Alcoholics by Speckle Tracking Echocardiography**  
KÜÇÜK M., Oncel C. R., Yildirjm A. B., Canan F., Kuloglu M. M.  
BIOMED RESEARCH INTERNATIONAL, vol.2017, 2017 (SCI-Expanded)
- VIII. **Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome**  
akyol E. S., albayrak Y., beyazyüz M., aksoy N., Kuloglu M. M., Hashimoto K.  
NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.11, pp.865-872, 2015 (SCI-Expanded)
- IX. **Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia**  
Albayrak Y., Beyazyuz M., Beyazyuz E., Kuloglu M. M.  
NORDIC JOURNAL OF PSYCHIATRY, vol.68, no.5, pp.341-346, 2014 (SCI-Expanded)
- X. **Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo**  
Yanik M. E., ERFAN G., Albayrak Y., Aydin M., Kulac M., Kuloglu M. M.  
NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.10, pp.2361-2367, 2014 (SCI-Expanded)
- XI. **A Catatonic Schizophrenia Case Treated Effectively with Aripiprazole**  
Albayrak Y., Kuloglu M. M.  
KLINİK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.23, no.3, pp.257-260, 2013 (SCI-Expanded)
- XII. **Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: A preliminary study**  
ALBAYRAK Y., Unsal C., BEYAZYÜZ M., Unal A., Kuloglu M. M.  
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.45, pp.144-149, 2013 (SCI-Expanded)
- XIII. **Temperament and Character Traits and Alexithymia in Patients with Multiple Sclerosis**  
Kuloglu M. M., Saglam S., korkmaz S., sađlam S., Gurok M. G., Karti Ustun S., Bulut S.  
NOROSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.50, no.1, pp.34-39, 2013 (SCI-Expanded)

- XIV. **Psychotic Disorder due to Withdrawal of Barbexaclone**  
Kuloglu M. M., korkmaz S., sađlam S., Atmaca M.  
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.50, no.1, pp.87-88, 2013 (SCI-Expanded)
- XV. **Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine**  
Unsal C., Albayrak Y., Albayrak N., Kuloglu M., Hashimoto K.  
NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.9, pp.1545-1552, 2013 (SCI-Expanded)
- XVI. **Olanzapine Induced Hair Loss: A Case Report**  
Kuloglu M. M., korkmaz S., kılıç N., Sađlam S., Gurok M. G., Atmaca M.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.22, no.4, pp.362-365, 2012 (SCI-Expanded)
- XVII. **Visual hallucinations associated with bupropion use: a case report**  
korkmaz S., Kuloglu M. M., sađlam S., Atmaca M.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.22, no.2, pp.187-189, 2012 (SCI-Expanded)
- XVIII. **A Case of Borderline Erotomania Accompanying Obsessive Compulsive Disorder and Psychogenic Polydipsia: Case Report**  
korkmaz S., Kuloglu M. M., bahçeci B., Atmaca M.  
TURKIYE KLİNİKLERİ TIP BİLİMLERİ DERGİSİ, vol.32, no.1, pp.271-275, 2012 (SCI-Expanded)
- XIX. **Galactorrhea During Duloxetine Treatment: A Case Report**  
korkmaz S., Kuloglu M. M., ışık U., sađlam S., Atmaca M.  
TURK PSIKIYATRI DERGİSİ, vol.22, no.3, pp.200-201, 2011 (SSCI)
- XX. **Olfactory reference syndrome treated with quetiapine: a case**  
Atmaca M., korkmaz S., namlı M. N., korkmaz H., Kuloglu M. M.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.3, pp.246-248, 2011 (SCI-Expanded)
- XXI. **Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature**  
Kuloglu M. M., ikinci O., albayrak Y., çayköylü A.  
ARCHIVES OF WOMENS MENTAL HEALTH, vol.13, no.5, pp.443-447, 2010 (SCI-Expanded)
- XXII. **Phenomenology of Delusions and Hallucinations in Patients with Schizophrenia**  
Gecici O., Kuloglu M., Guler O., Ozbulut O., Kurt E., Onen S., Ekinci O., Yesilbas D., Caykoylu A., Emul M., et al.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.20, no.3, pp.204-212, 2010 (SCI-Expanded)
- XXIII. **Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone**  
Kuloglu M. M., ikinci o., çayköylü a.  
JOURNAL OF PSYCHOPHARMACOLOGY, vol.24, no.4, pp.627-628, 2010 (SCI-Expanded)
- XXIV. **Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use**  
Kuloglu M. M., çayköylü a., ikinci o., bayındırlı d., vural g., deniz o.  
JOURNAL OF PSYCHOPHARMACOLOGY, vol.24, no.4, pp.623-624, 2010 (SCI-Expanded)
- XXV. **Aripiprazole-induced rabbit syndrome: a case report**  
çayköylü a., ikinci o., Kuloglu M. M., deniz o.  
JOURNAL OF PSYCHOPHARMACOLOGY, vol.24, no.3, pp.429-431, 2010 (SCI-Expanded)
- XXVI. **A case study of Neuro-psycho-Behcet's Syndrome presenting with psychotic attack**  
deniz O., çayköylü A., Vural G., albayrak Y., temel S., aydın I., Kuloglu M. M.  
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.111, no.10, pp.877-879, 2009 (SCI-Expanded)
- XXVII. **Obsessive Symptoms Associated with Lamotrigine use in a Patient with Bipolar II Disorder**  
Kuloglu M. M., ikinci O., yılmaz E., çayköylü A.  
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.19, no.4, pp.414-416,

2009 (SCI-Expanded)

- XXVIII. **Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report**  
Kuloglu M. M., çayköylü A., ikinci O., yılmaz E.  
JOURNAL OF PSYCHOPHARMACOLOGY, vol.23, no.8, pp.1001-1003, 2009 (SCI-Expanded)
- XXIX. **Arnold-Chiari I malformation association with generalized anxiety disorder: A case report**  
çayköylü A., ikinci O., albayrak Y., Kuloglu M. M., deniz O.  
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.6, pp.1613-1614, 2008 (SCI-Expanded)
- XXX. **A left temporal lobe arachnoid cyst in a patient with schizophrenia-like psychosis: A case report**  
Kuloglu M. M., çayköylü A., yılmaz E., ikinci O.  
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.5, pp.1353-1354, 2008 (SCI-Expanded)
- XXXI. **Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: A case report**  
çayköylü A., ikinci O., Kuloglu M. M.  
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.5, pp.1349-1350, 2008 (SCI-Expanded)
- XXXII. **Antioxidant enzyme and malondialdehyde levels in patients with social phobia**  
Atmaca M., Kuloglu M. M., Tezca E., Ustundag B.  
PSYCHIATRY RESEARCH, vol.159, no.1-2, pp.95-100, 2008 (SCI-Expanded)
- XXXIII. **Serum leptin and cholesterol values in violent and non-violent suicide attempters**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B.  
PSYCHIATRY RESEARCH, vol.158, no.1, pp.87-91, 2008 (SCI-Expanded)
- XXXIV. **The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia**  
Atmaca M., Tezcan E., Kuloglu M. M., Ustundag B., Kirtas O.  
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.59, no.6, pp.652-656, 2005 (SCI-Expanded)
- XXXV. **Serum folate and homocysteine levels in patients with obsessive-compulsive disorder**  
Atmaca M., Tezcan E., Kuloglu M. M., Kirtas O., Ustundag B.  
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.59, no.5, pp.616-620, 2005 (SCI-Expanded)
- XXXVI. **Plasma nitrate values in patients with obsessive-compulsive disorder**  
Atmaca M., Tezcan E., Kuloglu M. M., Ustundag B.  
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.59, no.5, pp.621-623, 2005 (SCI-Expanded)
- XXXVII. **Serum leptin levels in obsessive-compulsive disorder**  
Atmaca M., Tezcan E., Kuloglu M. M., Ustundag B.  
PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol.59, no.2, pp.189-193, 2005 (SCI-Expanded)
- XXXVIII. **A new atypical antipsychotic: quetiapine-induced sexual dysfunctions**  
Atmaca M., Kuloglu M. M., Tezcan E.  
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, vol.17, no.2, pp.201-203, 2005 (SCI-Expanded)
- XXXIX. **Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment**  
Atmaca M., Tezcan E., Kuloglu M. M., Ustundag B., Tunckol H.  
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.254, no.4, pp.231-235, 2004 (SCI-Expanded)
- XL. **Nizatidine for the treatment of patients with quetiapine-induced weight gain**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B., Kilic N.  
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.19, no.1, pp.37-40, 2004 (SCI-Expanded)
- XLI. **Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B.  
ACTA PSYCHIATRICA SCANDINAVICA, vol.108, no.3, pp.208-214, 2003 (SCI-Expanded)
- XLII. **An open clinical trial of reboxetine in the treatment of social phobia**

- Atmaca M., Tezcan E., Kuloglu M. M.  
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol.23, no.4, pp.417-419, 2003 (SCI-Expanded)
- XLIII. **Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B.  
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.18, no.6, pp.457-461, 2003 (SCI-Expanded)
- XLIV. **Switching to tianeptine in patients with antidepressant-induced sexual dysfunction**  
Atmaca M., Kuloglu M. M., Tezcan E., Buyukbayram A.  
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.18, no.4, pp.277-280, 2003 (SCI-Expanded)
- XLV. **Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B.  
JOURNAL OF CLINICAL PSYCHIATRY, vol.64, no.5, pp.598-604, 2003 (SCI-Expanded)
- XLVI. **Free radicals in patients with post-traumatic stress disorder**  
Tezcan E., Atmaca M., Kuloglu M. M., Ustundag B.  
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.253, no.2, pp.89-91, 2003 (SCI-Expanded)
- XLVII. **Serum leptin levels in patients with premature ejaculation before and after citalopram treatment**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B., Semercioz A.  
BJU INTERNATIONAL, vol.91, no.3, pp.252-254, 2003 (SCI-Expanded)
- XLVIII. **Neopterin production in posttraumatic stress disorder before and after pharmacotherapy**  
Atmaca M., Tezcan E., Kuloglu M. M., Onal S.  
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.253, no.1, pp.34-36, 2003 (SCI-Expanded)
- XLIX. **The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study**  
Atmaca M., Kuloglu M. M., Tezcan E., Semercioz A.  
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, vol.14, no.6, pp.502-505, 2002 (SCI-Expanded)
- L. **Sildenafil use in patients with olanzapine-induced erectile dysfunction**  
Atmaca M., Kuloglu M. M., Tezcan E.  
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, vol.14, no.6, pp.547-549, 2002 (SCI-Expanded)
- LI. **Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings**  
Atmaca M., Kuloglu M. M., Tezcan E., Unal A.  
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.17, no.8, pp.401-405, 2002 (SCI-Expanded)
- LII. **Quetiapine-associated and dose-related hypomania in a woman with schizophrenia**  
Atmaca M., Kuloglu M. M., Buyukbayram A., Tezcan E.  
EUROPEAN PSYCHIATRY, vol.17, no.5, pp.292-293, 2002 (SCI-Expanded)
- LIII. **Serum leptin levels in patients with premature ejaculation**  
Atmaca M., Kuloglu M. M., Tezcan E., Semercioz A., Ustundag B., Ayar A.  
ARCHIVES OF ANDROLOGY, vol.48, no.5, pp.345-350, 2002 (SCI-Expanded)
- LIV. **Neopterin levels and dexamethasone suppression test in posttraumatic stress disorder**  
Atmaca M., Kuloglu M. M., Tezcan E., Onal S., Ustundag B.  
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, vol.252, no.4, pp.161-165, 2002 (SCI-Expanded)
- LV. **Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder**  
Kuloglu M. M., Ustundag B., Atmaca M., CANATAN H., Tezcan A., Cinkilinc N.  
CELL BIOCHEMISTRY AND FUNCTION, vol.20, no.2, pp.171-175, 2002 (SCI-Expanded)
- LVI. **"The detergent is circulating in my blood": a case report**  
Atmaca M., Kuloglu M. M., Tezcan E., Unal A.  
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, vol.6, no.2, pp.117-119, 2002 (SCI-Expanded)
- LVII. **Bone metabolism and bone mineral density in premenopausal women with mild depression**  
kavuncu V., Kuloglu M. M., Kaya A., Sahin S., Atmaca M., Firidin B.

- YONSEI MEDICAL JOURNAL, vol.43, no.1, pp.101-108, 2002 (SCI-Expanded)
- LVIII. **Serum leptin and cholesterol levels in patients with bipolar disorder**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B., Bayik Y.  
NEUROPSYCHOBIOLOGY, vol.46, no.4, pp.176-179, 2002 (SCI-Expanded)
- LIX. **Weight gain and serum leptin levels in patients on lithium treatment**  
Atmaca M., Kuloglu M. M., Tezcan E., Ustundag B.  
NEUROPSYCHOBIOLOGY, vol.46, no.2, pp.67-69, 2002 (SCI-Expanded)
- LX. **Antioxidant enzyme and malondialdehyde levels in patients with panic disorder**  
Kuloglu M. M., Atmaca M., Tezcan E., Ustundag B., Bulut S.  
NEUROPSYCHOBIOLOGY, vol.46, no.4, pp.186-189, 2002 (SCI-Expanded)
- LXI. **Comparison of sociodemographic, clinical and phenomenological characteristics of Turkish and French patients suffering from obsessive-compulsive disorder**  
Millet B., Leclaire M., Bourdel M., Loo H., Tezcan E., Kuloglu M. M.  
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, vol.45, no.9, pp.848, 2000 (SCI-Expanded)

## Articles Published in Other Journals

- I. **HCV Genotype Distribution Among People Who Inject Drug in Turkey: Findings from Multicenter and Cross-Sectional Study**  
Dilbaz N., Kuloğlu M., Evren E. C., Paltun S. C., Bilici R., Noyan C. O., KULAKSIZOĞLU B., Karabulut V., Umut G., Unubol B., et al.  
Substance Abuse: Research and Treatment, vol.17, 2023 (ESCI)
- II. **The relationship of serum leptin and ghrelin levels with craving and withdrawal in opioid use disorder**  
KARA H., ERDOĞAN A., Akbas H., KULOĞLU M. M.  
Anadolu Psikiyatri Dergisi, vol.22, no.4, pp.200-205, 2021 (Scopus)
- III. **Tattooing and Its Relationship with Impulsivity in Substance Use Disorder Madde Kullanım Bozukluğunda Dövme Özellikleri ve Dövmenin Dürtüsellik ile İlişkisi**  
ERDOĞAN A., Kara H., KÖSE F., CİNEMRE B., KULAKSIZOĞLU B., Kuloğlu M. M.  
Neuropsychiatric Investigation, vol.59, no.1, pp.1-7, 2021 (Scopus)
- IV. **Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder**  
ERDOĞAN A., KULAKSIZOĞLU B., BİNGÖL M. S., CİNEMRE B., Kuloglu M. M.  
Dusunen Adam - The Journal of Psychiatry and Neurological Sciences, vol.34, no.1, pp.102-106, 2021 (ESCI)
- V. **Madde Kullanım Bozukluğu Tedavisinde Bir Yıllık Tedavide Kalma Oranları: Geriye Dönük Bir Çalışma**  
KULAKSIZOĞLU B., BİNGÖL M. S., GÜLENGÖZ M., KULOĞLU M. M.  
FIRAT TIP DERGİSİ, vol.25, no.1, pp.43-47, 2020 (Peer-Reviewed Journal)
- VI. **Personality, temperament traits and impulsivity levels in opiate use disorder patients with and without intravenous use İntravenöz kullanımı olan ve olmayan opiyat kullanım bozukluğu hastalarında kişilik, mizaç özellikleri ve dürtüsellik düzeyleri**  
ERDOĞAN A., CİNEMRE B., KULAKSIZOĞLU B., Kuloğlu M. M.  
Yeni Symposium, vol.58, no.3, pp.2-6, 2020 (Scopus)
- VII. **The Effect Of The Psychoeducation In The Psychiatric Day Hospital On The Selfefficacy And Well-Being Of The Patients**  
KESER İ., ÇAYNAK S., ERGÜN G., SAKİNER A., KULOĞLU M. M.  
JOURNAL OF PSYCHIATRIC NURSING, vol.9, no.1, pp.119-120, 2018 (Peer-Reviewed Journal)
- VIII. **Psikiyatri Gündüz Hastanesinde Verilen Psikoeğitimin Hastaların Öz Yeterlilik ve İyi Haline Etkisi The Effect Of The Psychoeducation In The Psychiatric Day Hospital On The Selfefficacy And Well-**

## Being Of The Patients

Keser İ., Çaynak S., Ergün G., Sakiner A., Kuloğlu M. M.

JOURNAL OF PSYCHIATRIC NURSING, vol.9, no.1, pp.119-120, 2018 (Peer-Reviewed Journal)

## Refereed Congress / Symposium Publications in Proceedings

- I. **Crime Profiles of Patients Applying for Addiction Treatment Between 2013-2018**  
Uluoyol F. M., Bayraktar S., Kuloğlu M. M.  
1. Uluslararası 17. Ulusal Adli Bilimler Kongresi, Antalya, Turkey, 12 - 15 November 2020, pp.168
- II. **HEPATITIS C VIRUS (HCV) GENOTYPE DISTRIBUTION AMONG INTRAVENOUS DRUG USERS (IVDU) AND HCV INFECTED PATIENTS UNRELATED TO DRUG USE**  
ERMAN DALOĞLU C. A., PARKAN Ö. M., ERDOĞAN A., İNAN D., KULOĞLU M. M., MUTLU D., ÇOLAK D.  
22st ESCV (European Society for Clinical Virology), Copenhag, Denmark, 10 - 14 September 2019, pp.231
- III. **HEPATITIS C VIRUS (HCV) GENOTYPE DISTRIBUTION AMONG INTRAVENOUS DRUG USERS (IVDU) AND HCV INFECTED PATIENTS UNRELATED TO DRUG USE**  
ERMAN DALOĞLU C. A., PARKAN Ö. M., ERDOĞAN A., İNAN D., KULOĞLU M. M., MUTLU D., ÇOLAK D.  
22st ESCV (European Society for Clinical Virology), Copenhag, Denmark, 10 - 14 September 2019, pp.231
- IV. **HEPATITIS C VIRUS (HCV) GENOTYPE DISTRIBUTION AMONG INTRAVENOUS DRUG USERS (IVDU) AND HCV INFECTED PATIENTS UNRELATED TO DRUG USE**  
ERMAN DALOĞLU C. A., PARKAN Ö. M., ERDOĞAN A., İNAN D., KULOĞLU M. M., MUTLU D., ÇOLAK D.  
22st ESCV (European Society for Clinical Virology), Copenhag, Denmark, 10 - 14 September 2019, pp.231
- V. **Psikiyatri Gündüz Hastanesinde Verilen Psikoëğitimin Hastaların Öz Yeterlilik ve İyilik Haline Etkisi**  
KESER İ., ÇAYNAK S., ERGÜN G., sakiner a., KULOĞLU M. M.  
V.ULUSLARARASI IX.ULUSAL PSİKİYATRİ HEMŞİRELİĞİ KONGRESİ, Antalya, Turkey, 20 - 23 November 2018, pp.1902-1905
- VI. **Aripiprazole-induced allergy: case report**  
KARA H., DEMİREĞEN Ö., BALCI M. M., KULOĞLU M. M., TOMAR T.  
10. Uluslararası Psikofarmakoloji Kongresi ve 6. Uluslararası Çocuk ve Ergen Psikofarmakolojisi Sempozyumu, Antalya, Turkey, 25 - 29 April 2018, vol.2018:28, pp.140-141
- VII. **Lamotrigine-induced Stevens-Johnson Syndrome**  
KARA H., DEMİREĞEN Ö., BALCI M. M., KULOĞLU M. M., TOMAR T.  
10. Uluslararası Psikofarmakoloji Kongresi & 6. Uluslararası Çocuk ve Ergen Psikofarmakolojisi Sempozyumu, Antalya, Turkey, 25 - 29 April 2018, vol.2018:28, pp.237-238
- VIII. **Codeine Content Drug Abuse and Alcohol Use Disorder: A Case Report**  
KARA H., BALCI M. M., KULOĞLU M. M.  
9. Uluslararası Psikofarmakoloji Kongresi ve 5. Uluslararası Çocuk ve Ergen Psikofarmakolojisi Sempozyumu, Antalya, Turkey, 26 - 30 April 2017, vol.2017:27, pp.106
- IX. **BİR ÜNİVERSİTE HASTANESİ ALKOL VE MADDE BAĞIMLILIĞI ARAŞTIRMA VE UYGULAMA MERKEZİ NE BAŞVURAN HASTALARIN SOSYODEMOGRAFİK ÖZELLİKLERİ MADDE KULLANIM DURUMLARI VE TEDAVİYE ERİŞİMLERİ**  
BAŞAK G., ÖZDEMİR F., KULOĞLU M. M., DÖNMEZ L.  
18.Ulusal Halk Sağlığı Kongresi, Turkey, 5 - 09 October 2015, pp.1107-1108

## Metrics

Publication: 78

Citation (WoS): 1482

Citation (Scopus): 1692

H-Index (WoS): 21

H-Index (Scopus): 22

## Congress and Symposium Activities

8. Ulusal Alkol ve Madde Bağımlılığı Kongresi, Session Moderator, İzmir, Turkey, 2013
5. Uluslararası Psikofarmakoloji Kongresi, Panelists, Antalya, Turkey, 2013
8. Ulusal Biyolojik Psikiyatri Kongresi, Panelists, İstanbul, Turkey, 2011
18. Anadolu Psikiyatri Günleri, Panelists, Afyonkarahisar, Turkey, 2009
14. Ulusal Sosyal Psikiyatri Kongresi, Session Moderator, İstanbul, Turkey, 2007
6. Ulusal Biyolojik Psikiyatri Kongresi, Panelists, Mersin, Turkey, 2007
14. Ulusal Sosyal Psikiyatri Kongresi, Session Moderator, İstanbul, Turkey, 2007
12. Anadolu Psikiyatri Günleri, Panelists, Elazığ, Turkey, 2003

## Awards

- KULOĞLU M. M., "Atipik özellikler gösteren depresif bozuklukta yüksek serum leptin düzeyi", Türkiye Psikiyatri Derneği 8. Bahar Sempozyumu Duygudurum Bozuklukları Araştırma Üçüncülük Ödülü, April 2004
- KULOĞLU M. M., "Quetiapine Augmentation in Patients with Treatment Resistant Obsessive-Compulsive Disorder: a Single Blind, Placebo-Controlled Study", Türkiye Sosyal Psikiyatri Prof. Dr. Rasim ADASAL Ödülü, April 2003